Our research expertise on biological mechanisms and pathways has enabled us to develop a pipeline of drug candidates designed to address important unmet clinical needs, including better management of complications related to kidney and cardiovascular diseases, with the goal of improving outcomes for this large population of underserved patients. Our lead candidate tenapanor, is a first-in-class, targeted, small molecule for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis. We are also developing earlier-stage candidates that further leverage our discovery capabilities and deep understanding of transport mechanisms, targeting specific pharmacologic pathways. Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX. Tapping into the best talent on both coasts and everywhere in between, we maintain dual headquarters in the greater San Francisco and Boston biotech communities.
Location: United States, California, Fremont
Employees: 51-200
Phone: +1 510-745-1700
Total raised: $82.5M
Founded date: 2007
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Presidio P... | presidiopa... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.02.2022 | - | $27.5M | - |
| 15.05.2014 | - | $25M | - |
| 31.08.2011 | Series B | $30M | - |
Mentions in press and media 18
| Date | Title | Description | Source |
| 02.03.2023 | Ardelyx Reports Fourth Quarter and Full Year 2022 Financial ... | /EIN News/ -- Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net produ... | einpresswi... |
| 03.09.2021 | Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Tr... | FREMONT, Calif. and WALTHAM, Mass., Sept. 3, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a ... | prnewswire... |
| 29.07.2021 | Ardelyx Receives Complete Response Letter from U.S. FDA for ... | FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a ... | prnewswire... |
| 29.07.2021 | Ardelyx : Receives Complete Response Letter from U.S. FDA fo... | FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a bi... | marketscre... |
| 07.06.2021 | Ardelyx Announces Presentations at ERA-EDTA Virtual Congress... | FREMONT, Calif. and WALTHAM, June 7, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharm... | prnewswire... |
| 29.04.2021 | Ardelyx Announces Extension of the PDUFA Review Period for T... | FREMONT, Calif. and WALTHAM, Mass., April 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a... | prnewswire... |
| 14.04.2021 | Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initia... | FREMONT, Calif. and WALTHAM, Mass., April 14, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a... | prnewswire... |
| 12.04.2021 | Ardelyx Announces Upcoming Data Presentation at ISN World Co... | FREMONT, Calif. and WALTHAM, Mass., April 12, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a... | prnewswire... |
| 30.03.2021 | Ardelyx Announces Poster Presentations, Educational Symposiu... | FREMONT, Calif. and WALTHAM, Mass., March 30, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a... | prnewswire... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanc... | As the FDA’s decision date on Ardelyx’s lead drug, tenapanor, for use in irritable bowel syndrome lo... | endpts.com... |
Show more